Prolactin releasers

Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids

Retrieved on: 
Tuesday, July 20, 2021
Drugs, Chemical compounds, Chemistry, Combination drugs, Estrogens, Estranes, Prolactin releasers, GnRH antagonists, Relugolix/estradiol/norethisterone acetate, Uterine fibroid, Relugolix, Estradiol

With this approval, women and doctors finally have a long-term treatment option, which is important for the management of this condition.

Key Points: 
  • With this approval, women and doctors finally have a long-term treatment option, which is important for the management of this condition.
  • Todays approval of RYEQO, the first and only once-daily long-term treatment for women with uterine fibroids in Europe, marks a major milestone in expanding non-invasive treatment options for this common and potentially debilitating disease, said David Marek, Chief Executive Officer of Myovant Sciences, Inc.
  • Through our partnership with Gedeon Richter, we look forward to supporting even more women suffering from uterine fibroids.
  • RYEQO (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

City of Hope-Led Research Identifies How the Most Common Type of Breast Cancer Becomes Resistant to Treatment

Retrieved on: 
Thursday, June 24, 2021
Research, Other Health, General Health, Pharmaceutical, Oncology, Consumer, Clinical trials, Science, Biotechnology, Women, Stem cells, Health, Other Science, Endocrine system, Hormones, Organ systems, Breast cancer, Hepatotoxins, Prolactin releasers, Hormone receptor positive breast tumor, Estrogen receptor, Estrogen, Cancer, Estrogen deprivation therapy, Antihormone therapy

City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer .

Key Points: 
  • City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer .
  • About 80% of breast cancer cases are hormone receptor positive, meaning that these cancer cells need estrogen or progesterone to grow, according to the American Cancer Society .
  • Doctors currently treat people with estrogen receptor positive (ER+) breast cancer using therapy that inhibits both estrogen levels and cell cycle activity.
  • City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.

Lyndra Therapeutics Completes $60.5 Million Series C Financing

Retrieved on: 
Thursday, June 24, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Chemical compounds, Organic compounds, Drugs, Prolactin releasers, Atypical antipsychotics, Lactams, Mood stabilizers, Piperidines, Risperidone, Schizophrenia

Lyndra Therapeutics , a clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, today announced the closing of its $60.5 million Series C financing.

Key Points: 
  • Lyndra Therapeutics , a clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, today announced the closing of its $60.5 million Series C financing.
  • View the full release here: https://www.businesswire.com/news/home/20210624005094/en/
    Lyndras ultra-long-acting, extended-release oral capsule dosage form technology is the first of its kind.
  • Our trailblazing lead product candidate is a once-weekly oral risperidone treatment which has the potential to provide a meaningful benefit to the over two million people with schizophrenia, their caregivers and healthcare providers, said Dr. Patricia Hurter, Chief Executive Officer of Lyndra Therapeutics.
  • Lyndra has raised almost $250 million in funding, inclusive of this round.

Affron Associated with Improvements in Psychological Symptoms of Menopause According to New Study

Retrieved on: 
Tuesday, June 15, 2021
Hormones, Endocrine system, Organ systems, Hepatotoxins, Prolactin releasers, Spices, Pregnanes, Progestogens, Menopause, Estrogen, Saffron, Medroxyprogesterone acetate

The saffron extract, administered for 12 weeks at 28 mg at day, was associated with greater improvements in psychological symptoms.

Key Points: 
  • The saffron extract, administered for 12 weeks at 28 mg at day, was associated with greater improvements in psychological symptoms.
  • Affron is produced and marketed by Pharmactive using green proprietary technology to extract pure, highly concentrated saffron.
  • "This is the first study of affron examining menopause symptoms in average perimenopausal women," explains Alberto Espinel, Manager of Strategic R&D in Active and Functional Natural Ingredients for Pharmactive.
  • "This means that in comparison to other botanical extracts that target menopause symptoms, affron doesn't have undesirable estrogenic effects.

Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti®

Retrieved on: 
Wednesday, June 2, 2021
Medical specialties, Gastroenterology, Digestive diseases, Antiemetics, Chloroarenes, Prolactin releasers, 5-HT3 antagonists, Gastroparesis, Metoclopramide, Food and Drug Administration, United States patent law

Gimoti is Evokes nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis.

Key Points: 
  • Gimoti is Evokes nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis.
  • The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Gimoti in June 2020.
  • We are pleased to announce the issuance of this new U.S. patent which further validates that Gimoti is innovative and novel.
  • The issuance of this patent strengthens the intellectual property protection for Gimoti and supports our commercial efforts to make Gimoti the treatment of choice in the gastroparesis market.

Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Gastroenterology, Clinical medicine, Chloroarenes, Antiemetics, Prolactin releasers, Dosage forms, Gastroparesis, Metoclopramide, Forward-looking statement, Nasal spray

You report side effects related to Evoke Pharma products by calling 1-833-4-GIMOTI (1-833-444-6684) or emailing [email protected].

Key Points: 
  • You report side effects related to Evoke Pharma products by calling 1-833-4-GIMOTI (1-833-444-6684) or emailing [email protected].
  • The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
  • Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.
  • These forward-looking statements include statements regarding Evokes expectations on the social media marketing campaign.

TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

Retrieved on: 
Tuesday, May 25, 2021
Women, Consumer, Health, Pharmaceutical, Baby, Maternity, Drugs, Steroids, Sex hormones, Pregnanes, Progestogens, Diketones, Hepatotoxins, Prolactin releasers, Estradiol/progesterone, Estradiol, Progesterone, Estrone, BIJUVA, TherapeuticsMD, Inc., BIJUVA, THERAPEUTICSMD, INC.

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, announced today that the Company submitted a supplemental New Drug Application (sNDA) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration (FDA).

Key Points: 
  • TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, announced today that the Company submitted a supplemental New Drug Application (sNDA) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration (FDA).
  • We are pleased to have identified a path forward for submission to the FDA of our sNDA for low-dose BIJUVA.
  • BIJUVA is the only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule.
  • To learn more about TherapeuticsMD, please visit therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Global Transdermal Skin Patches Market Report 2021-2026: Players Gaining Attention Include Teva Pharmaceuticals, Novartis AG, Teikoku Pharma, Mylan, 3M - ResearchAndMarkets.com

Retrieved on: 
Monday, May 17, 2021
Surgery, Health, Sex hormones, Drugs, Organic compounds, Estranes, Hormonal contraception, Hepatotoxins, Prolactin releasers, Phenols, Levonorgestrel, Contraceptive patch, Estradiol, Ethinylestradiol

For instance, in February 2020, the US FDA approved the Contraceptive Patch known has Twirla (levonorgestrel and Ethinylestradiol) Transdermal System, it is a New Weekly Contraceptive Patch from the company, Agile Therapeutics Inc..

Key Points: 
  • For instance, in February 2020, the US FDA approved the Contraceptive Patch known has Twirla (levonorgestrel and Ethinylestradiol) Transdermal System, it is a New Weekly Contraceptive Patch from the company, Agile Therapeutics Inc..
  • Smoking damages lung function and makes it harder for the body to fight off coronaviruses and other infections.
  • According to the World Health Organization, 8 million people die each year as a result of smoking.
  • About 16 million Americans live with a smoking-related disease.

Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Wednesday, May 12, 2021
Sex hormones, Drugs, Organic compounds, Estranes, Hormonal contraception, Hepatotoxins, Prolactin releasers, Phenols, XC2, Levonorgestrel, Estradiol, Ethinylestradiol

b"PRINCETON, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women\xe2\x80\x99s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET.\nThe fireside chat will be webcast live and can be accessed in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/ , or by clicking here: https://event.on24.com/wcc/r/3173531/F391B23E756682EFEFE4952267784F45\nThe webcast will be archived on the Agile Therapeutics website for 30 days following the event.\nAgile Therapeutics\xc2\xa0is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today\xe2\x80\x99s women.\xc2\xa0Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.\xc2\xa0Our initial product, Twirla\xc2\xae, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive.

Key Points: 
  • b"PRINCETON, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women\xe2\x80\x99s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET.\nThe fireside chat will be webcast live and can be accessed in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/ , or by clicking here: https://event.on24.com/wcc/r/3173531/F391B23E756682EFEFE4952267784F45\nThe webcast will be archived on the Agile Therapeutics website for 30 days following the event.\nAgile Therapeutics\xc2\xa0is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today\xe2\x80\x99s women.\xc2\xa0Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.\xc2\xa0Our initial product, Twirla\xc2\xae, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive.
  • Twirla is based on our proprietary transdermal patch technology, called Skinfusion\xc2\xae, which is designed to allow drug delivery through the skin.
  • For more information, please visit the company website at www.agiletherapeutics.com .
  • The Company may occasionally disseminate material, nonpublic information on the Company\xe2\x80\x99s website.\n"

U.S. FDA Approves NEXTSTELLIS®, New Oral Contraceptive

Retrieved on: 
Friday, April 16, 2021
Sex hormones, Drugs, Hormones, Hepatotoxins, Progestogens, Hormonal contraception, Prolactin releasers, Estranes, Birth control, Medroxyprogesterone acetate, Estrogen, Emergency contraception

"\nNearly 10 million American women use short-acting combination contraceptives (estrogen and progestin).

Key Points: 
  • "\nNearly 10 million American women use short-acting combination contraceptives (estrogen and progestin).
  • It has more selective activity in tissues, focusing on those needed to support contraceptive efficacy, cycle control and other beneficial effects of estrogen.
  • According to phase 3 study findings, NEXTSTELLIS demonstrated contraceptive efficacy across all subgroups by age, BMI1 and prior hormonal contraception use.
  • The company has an extensive Women\'s Health portfolio focused on contraceptives, including its flagship birth control product, NEXTSTELLIS.